2122 Treatment outcomes according to extended RAS mutation testing in a phase II study of first-line mFOLFOX plus cetuximab followed by cetuximab in monotherapy as maintenance therapy or mFOLFOX plus cetuximab in patients with metastatic colorectal cancer: The MACRO-2 trial
Aranda, E., García-Alfonso, P., Benavides, M., Sanchez-Ruiz, A., Guillen-Ponce, C., Safont, M.J., Alcaide, J., Gomez, A., Lopez, R., Manzano, J.L., Mendez-Urena, M., Lopez, C., García-Paredes, B., GráVolume:
51
Langue:
english
Journal:
European Journal of Cancer
DOI:
10.1016/s0959-8049(16)31044-9
Date:
September, 2015
Fichier:
PDF, 73 KB
english, 2015
File converter
Plus de résultats de recherche
More benefits 
